JP2023514992A5 - - Google Patents
Info
- Publication number
- JP2023514992A5 JP2023514992A5 JP2022548518A JP2022548518A JP2023514992A5 JP 2023514992 A5 JP2023514992 A5 JP 2023514992A5 JP 2022548518 A JP2022548518 A JP 2022548518A JP 2022548518 A JP2022548518 A JP 2022548518A JP 2023514992 A5 JP2023514992 A5 JP 2023514992A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- weeks
- formulation according
- liquid
- dosage formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025162266A JP2026021305A (ja) | 2020-02-21 | 2025-09-29 | Ｇｌｐ－１ｒおよびｇｃｇｒアゴニスト、製剤、ならびに使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062980093P | 2020-02-21 | 2020-02-21 | |
| US62/980,093 | 2020-02-21 | ||
| US202063122108P | 2020-12-07 | 2020-12-07 | |
| US63/122,108 | 2020-12-07 | ||
| US202163133540P | 2021-01-04 | 2021-01-04 | |
| US63/133,540 | 2021-01-04 | ||
| PCT/US2021/018947 WO2021168386A1 (en) | 2020-02-21 | 2021-02-21 | Glp-1r and gcgr agonists, formulations, and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025162266A Division JP2026021305A (ja) | 2020-02-21 | 2025-09-29 | Ｇｌｐ－１ｒおよびｇｃｇｒアゴニスト、製剤、ならびに使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023514992A JP2023514992A (ja) | 2023-04-12 |
| JP2023514992A5 true JP2023514992A5 (https=) | 2024-03-01 |
| JP7752619B2 JP7752619B2 (ja) | 2025-10-10 |
Family
ID=77391258
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548518A Active JP7752619B2 (ja) | 2020-02-21 | 2021-02-21 | Ｇｌｐ－１ｒおよびｇｃｇｒアゴニスト、製剤、ならびに使用方法 |
| JP2025162266A Pending JP2026021305A (ja) | 2020-02-21 | 2025-09-29 | Ｇｌｐ－１ｒおよびｇｃｇｒアゴニスト、製剤、ならびに使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025162266A Pending JP2026021305A (ja) | 2020-02-21 | 2025-09-29 | Ｇｌｐ－１ｒおよびｇｃｇｒアゴニスト、製剤、ならびに使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210290732A1 (https=) |
| EP (1) | EP4106796A4 (https=) |
| JP (2) | JP7752619B2 (https=) |
| KR (1) | KR20220143923A (https=) |
| CN (1) | CN115427065A (https=) |
| AU (1) | AU2021224246A1 (https=) |
| BR (1) | BR112022016470A2 (https=) |
| CA (1) | CA3168001A1 (https=) |
| IL (1) | IL295744A (https=) |
| MX (1) | MX2022010320A (https=) |
| WO (1) | WO2021168386A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108892709A (zh) * | 2011-05-18 | 2018-11-27 | 欧莫德里斯制药公司 | 改良的肽药物 |
| MX360816B (es) * | 2012-11-20 | 2018-11-15 | Mederis Diabetes Llc | Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina. |
| US20230317230A1 (en) * | 2019-05-02 | 2023-10-05 | Closed Loop Medicine Ltd. | Method for treating obesity |
| CN117202924A (zh) * | 2020-12-07 | 2023-12-08 | 斯皮特弗尔制药有限责任公司 | 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法 |
| CN118234742A (zh) * | 2021-12-01 | 2024-06-21 | 江苏恒瑞医药股份有限公司 | Glp-1和gip受体双重激动剂的药物组合物及其用途 |
| JP2025537192A (ja) * | 2022-11-05 | 2025-11-14 | スピットファイア ファーマ エルエルシー | Ｇｌｐ－１ｒおよびｇｃｇｒアゴニストを使用した心血管リスク因子の処置のための治療レジメンおよび方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008513384A (ja) * | 2004-09-17 | 2008-05-01 | ノボ ノルディスク アクティーゼルスカブ | インスリンおよびインスリン分泌性ペプチドを含有する医薬組成物 |
| MX2007005521A (es) * | 2004-11-12 | 2007-05-18 | Novo Nordisk As | Formulaciones estables de peptidos insulinotropicos. |
| CN108892709A (zh) * | 2011-05-18 | 2018-11-27 | 欧莫德里斯制药公司 | 改良的肽药物 |
| MX360816B (es) * | 2012-11-20 | 2018-11-15 | Mederis Diabetes Llc | Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina. |
| ES2906975T3 (es) * | 2012-11-20 | 2022-04-21 | Eumederis Pharmaceuticals Inc | Productos farmacéuticos de péptidos mejorados |
| EP2986313B1 (en) * | 2013-04-18 | 2019-06-12 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| PT3155017T (pt) * | 2014-05-28 | 2024-05-14 | Mederis Diabetes Llc | Farmacêuticos peptídicos melhorados para resistência à insulina |
| JP2017517549A (ja) * | 2014-06-13 | 2017-06-29 | サノフイ | 活性薬剤成分のナノカプセル製剤 |
| PE20170471A1 (es) * | 2014-06-13 | 2017-05-14 | Santa Maria Biotherapeutics Inc | Polipeptidos receptores formulados y metodos relacionados |
| AU2015320545C1 (en) * | 2014-09-24 | 2020-05-14 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
| EP4523705A3 (en) * | 2015-06-30 | 2025-06-11 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| CN108718522A (zh) * | 2016-02-23 | 2018-10-30 | 赛森生物股份有限公司 | Il-6拮抗剂制剂及其用途 |
| EP4506017A3 (en) * | 2018-01-03 | 2025-05-14 | Mederis Diabetes, LLC | Improved peptide pharmaceuticals for treatment of nash and other disorders |
-
2021
- 2021-02-21 CA CA3168001A patent/CA3168001A1/en active Pending
- 2021-02-21 WO PCT/US2021/018947 patent/WO2021168386A1/en not_active Ceased
- 2021-02-21 IL IL295744A patent/IL295744A/en unknown
- 2021-02-21 EP EP21757069.6A patent/EP4106796A4/en active Pending
- 2021-02-21 AU AU2021224246A patent/AU2021224246A1/en active Pending
- 2021-02-21 CN CN202180029769.4A patent/CN115427065A/zh active Pending
- 2021-02-21 MX MX2022010320A patent/MX2022010320A/es unknown
- 2021-02-21 JP JP2022548518A patent/JP7752619B2/ja active Active
- 2021-02-21 US US17/180,827 patent/US20210290732A1/en active Pending
- 2021-02-21 KR KR1020227032683A patent/KR20220143923A/ko active Pending
- 2021-02-21 BR BR112022016470A patent/BR112022016470A2/pt unknown
-
2025
- 2025-01-22 US US19/034,251 patent/US20250262280A1/en active Pending
- 2025-09-29 JP JP2025162266A patent/JP2026021305A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023514992A5 (https=) | ||
| US20230226141A1 (en) | Angiotensin ii alone or in combination for the treatment of hypotension | |
| US8071368B2 (en) | Methods for promoting growth and survival of insulin-secreting cells | |
| CN118453597A (zh) | 用于治疗非酒精性脂肪性肝病和非酒精性脂肪性肝炎的组合物 | |
| JP2024545887A5 (https=) | ||
| WO2000033840A1 (en) | Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis | |
| Banerjee et al. | A novel peptide nanomedicine for treatment of pancreatogenic diabetes | |
| US20230092769A1 (en) | Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs | |
| Keenan et al. | Prolonged corticotrophic action of a synthetic substituted α1-18 ACTH | |
| Watanabe et al. | ACTH response in rats during biphasic fever induced by interleukin-1 | |
| US20160303199A1 (en) | Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound | |
| CN110170046A (zh) | 成纤维细胞生长因子21在制备治疗急性胰腺炎药物中的应用 | |
| AU2024234229A1 (en) | Annexin a1 administration regime | |
| WO2024042518A1 (en) | Glp-1 receptor antagonist and methods of use thereof | |
| Robertson et al. | Intravitreal injection of octreotide acetate | |
| US20260014233A1 (en) | Multi-dose pen of tirzepatide | |
| KR20250129611A (ko) | 약학 조합물 및 이의 용도 | |
| HK40094446A (zh) | Glp-1给药方案 | |
| WO2024189054A1 (en) | Annexin a1 delayed dosing | |
| US20230081034A1 (en) | Dosing regimen of glp-1 | |
| HK40128498A (zh) | 使用gip/glp1共激动剂用於治疗的方法 | |
| HK40128497A (zh) | 使用gip/glp1共激动剂用於治疗的方法 | |
| HK40127982A (zh) | 使用gip/glp1共激动剂用於治疗的方法 | |
| HK40082881A (en) | Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs | |
| AU2006250347A1 (en) | Agent for improvement of insulin resistance |